Surrogate End Points in Clinical Trials: Are We being Misled? Annals of Internal Medicine, vol.125, pp.605-613, 1996. ,
Intermediate Clinical Endpoints: A Bridge Between Progression-Free Survival and Overall Survival in Ovarian Cancer Trials, Cancer, vol.121, issue.11, pp.1737-1746, 2015. ,
Surrogate Endpoints in Clinical Trials: Cancer, Statistics in Medicine, vol.8, issue.4, pp.405-413, 1989. ,
Progression-Free Survival: Meaningful or Simply Measurable, Journal of Clinical Oncology, vol.30, issue.10, pp.1030-1033, 2012. ,
Surrogate Endpoints in Clinical Trials: Definition and operational criteria, Statistics in Medicine, vol.8, issue.4, pp.431-440, 1989. ,
The Validation of Surrogate Endpoints in Meta-Analyses of Randomized Experiments, Biostatistics, vol.1, issue.1, pp.49-67, 2000. ,
The Evaluation of Surrogate Endpoints, 2005. ,
Validation of Surrogate End Points in Multiple Randomized Clinical Trials with Failure Time End Points, Journal of the Royal Statistical Society C (Applied Statistics), vol.50, issue.4, pp.405-422, 2001. ,
Evaluation of Failure Time Surrogate Endpoints in Individual Patient Data Meta-Analyses, 2017. ,
Applied Surrogate Endpoint Evaluation Methods with SAS and R. Chapman and Hall/CRC, 2017. ,
Bayesian Adjusted R2 for the Meta-Analytic Evaluation of Surrogate Time-To-Event Endpoints in Clinical Trials, Statistics in Medicine, vol.31, issue.8, pp.743-761, 2012. ,
Comparative Assessment of Trial-Level Surrogacy Measures for Candidate Time-to-Event Surrogate Endpoints in Clinical Trials, Computational Statistics & Data Analysis, vol.55, issue.9, pp.2748-2757, 2011. ,
A Poisson Approach to the Validation of Failure Time Surrogate Endpoints in Individual Patient Data Meta-Analyses, Statistical Methods in Medical Research, vol.28, issue.1, pp.170-183, 2019. ,
Surrogate Marker Evaluation from an Information Theory Perspective. Biometrics, vol.63, p.17447943, 2007. ,
Leukemia-free Survival as a Surrogate End Point for Overall Survival in the Evaluation of Maintenance Therapy for Patients with Acute Myeloid Leukemia in Complete Remission, Haematologica, vol.96, issue.8, pp.1106-1112, 2011. ,
Statistical Evaluation of Surrogate Endpoints with Examples from, Cancer Clinical Trials. Biometrical Journal, vol.58, issue.1, pp.104-132, 2016. ,
One-step validation method for surrogate endpoints using data from multiple randomized cancer clinical trials with failure-time endpoints, Statistics in Medicine, vol.38, issue.16, pp.2928-2942, 2019. ,
The Robust Inference for the Cox Proportional Hazards Model, Journal of the American Statistical Association, vol.84, issue.408, pp.1074-1078, 1989. ,
Surrogate: Evaluation of Surrogate Endpoints, Clinical Trials, 2018. ,
Bayesian Meta-Analytical Methods to Incorporate Multiple Surrogate Endpoints in Drug Development Process. In: Statistics in medicine, 2016. ,
, Institute for Quality and Efficiency in Health Care. Validity of Surrogate Endpoints in Oncology: Executive Summary, 2011.
Surrogate Threshold Effect: An Alternative Measure for Meta-Analytic Surrogate Endpoint validation, Pharmaceutical Statistics, vol.5, issue.3, pp.173-186, 2006. ,
Tutorial in Joint Modeling and Prediction: A Statistical Software for Correlated Longitudinal Outcomes, Recurrent Events and a Terminal Event, Journal of Statistical Software, vol.81, issue.3, pp.1-52, 2017. ,
, Cyclophosphamide Plus Cisplatin Plus Adriamycin Persus Cyclophosphamide, Doxorubicin, and Cisplatin Chemotherapy of Ovarian Carcinoma: A Meta-Analysis. Classic Papers and Current Comments, vol.3, pp.237-234, 1991.
An Algorithm for Least-Squares Estimation of Nonlinear Parameters, Journal of the Society for Industrial and Applied Mathematics, vol.11, issue.2, pp.431-441, 1963. ,
A Penalized Likelihood Approach for Arbitrarily Censored and Truncated Data: Application to Age-Specific Incidence of Dementia, Biometrics, vol.54, issue.1, pp.185-194, 1998. ,
URL : https://hal.archives-ouvertes.fr/inserm-00182453
On Meta-Analytic Assessment of Surrogate Outcomes, Biostatistics, vol.1, issue.3, pp.231-246, 2000. ,
Joint Frailty Models for Recurring Events and Death Using Maximum Penalized Likelihood Estimation: Application on Cancer Events, Biostatistics, vol.8, issue.4, pp.708-721, 2007. ,
URL : https://hal.archives-ouvertes.fr/halshs-00121706
General Frailty Models: Shared, Joint and Nested Frailty Models with Prediction; Evaluation of Failure-Time Surrogate Endpoints, 2019. ,
Computation of Standard Errors, Health Services Research, vol.49, issue.2, pp.731-750, 2014. ,
The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-Analyses, JAMA Internal Medicine, vol.175, issue.8, pp.1389-1398, 2015. ,
Five Criteria for Using a Surrogate Endpoint to Predict Treatment Effect Based on Data from Multiple Previous Trials, Statistics in Medicine, vol.37, issue.4, pp.507-518, 2018. ,
Using simulation to optimize adaptive trial designs: applications in learning and confirmatory phase trials, Clinical Investigation, vol.5, issue.4, pp.401-413, 2015. ,
A Joint Frailty-Copula Model Between Tumour Progression and Death for Meta-Analysis. Statistical Methods in Medical Research, vol.26, pp.2649-2666, 2017. ,